Element Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

Element Capital Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-5,147	Closed	-$404K	–	508
2019 Q1	$404K	Buy	5,147 +1,157	+29%	+$87.7K	0.01%	505
2018 Q4	$338K	Sell	3,990 -484	-11%	-$51.6K	0.01%	412
2018 Q3	$766K	Buy	4,474 +1,744	+64%	+$263K	0.02%	379
2018 Q2	$353K	Sell	2,730 -123	-4%	-$13.7K	0.01%	487
2018 Q1	$294K	Buy	+2,853	New	+$282K	0.01%	484

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Element Capital Management's LGND Position: Q2 2019 in Review

Element Capital Management sold out of Ligand Pharmaceuticals (LGND) in Q2 2019, closing a stake of 5,147 shares — an estimated $404K sold.

Element Capital Management first reported a position in LGND in Q1 2018 and held it in 5 quarters. The position peaked at $766K in Q3 2018. 305 funds tracked by Wall St. Rank hold LGND as of Q2 2019.

Element Capital Management reported no remaining Ligand Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Element Capital Management sold 5,147 Ligand Pharmaceuticals shares in Q2 2019, an estimated $404K.
Element Capital Management first reported a position in Ligand Pharmaceuticals in Q1 2018 and held it in 5 quarters.
Element Capital Management's Ligand Pharmaceuticals position peaked at $766K in Q3 2018.
305 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2019.

Based on Element Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.